Financial Performance - The company's revenue for Q1 2024 was CNY 281,550,999.26, a decrease of 23.34% compared to CNY 367,275,121.57 in the same period last year[10]. - The net profit attributable to shareholders for Q1 2024 was CNY 58,039,870.20, down 46.46% from CNY 108,394,751.90 year-on-year[10]. - The net profit after deducting non-recurring gains and losses was CNY 55,717,163.28, a decrease of 44.38% compared to CNY 100,178,473.65 in the previous year[10]. - The basic earnings per share for Q1 2024 was CNY 0.14, down 48.15% from CNY 0.27 in the same period last year[10]. - Total operating revenue for the current period is $281.55 million, down from $367.28 million in the previous period, representing a decrease of approximately 23.3%[46]. - Net profit for the current period is $58.04 million, compared to $108.39 million in the previous period, reflecting a decline of approximately 46.4%[47]. - Total comprehensive income for the current period is $46.66 million, down from $103.42 million in the previous period, a decrease of approximately 54.8%[48]. Cash Flow and Assets - The net cash flow from operating activities increased by 19.25% to CNY 74,921,798.44 from CNY 62,825,635.11 in the same period last year[10]. - Cash inflows from operating activities were ¥299,924,478.89, down 26% from ¥404,771,442.02 in the previous period[30]. - Cash flow from operating activities generated a net amount of $74.92 million, an increase from $62.83 million in the previous period[50]. - Cash flow from investing activities resulted in a net outflow of $332.22 million, contrasting with a net inflow of $114.32 million in the previous period[50]. - Total assets at the end of the reporting period were CNY 3,567,154,985.08, reflecting a 1.25% increase from CNY 3,523,270,170.04 at the end of the previous year[10]. - Total current assets increased to ¥2,370,563,874.36 from ¥2,359,008,891.90, reflecting a growth of approximately 0.07%[55]. - Cash and cash equivalents decreased to ¥1,393,629,244.89 from ¥1,708,241,239.10, a decline of about 18.43%[54]. - Total non-current assets increased to ¥1,196,591,110.72 from ¥1,164,261,278.14, showing an increase of about 2.77%[55]. Liabilities and Equity - The total liabilities amounted to ¥338,204,829.28, a slight decrease from ¥340,982,554.64 in the previous period[27]. - The total equity attributable to shareholders reached ¥3,228,950,155.80, up from ¥3,182,287,615.40, indicating a growth of approximately 1.5%[27]. - The equity attributable to shareholders increased by 1.47% to CNY 3,228,950,155.80 from CNY 3,182,287,615.40 at the end of the previous year[10]. - Total current liabilities decreased to ¥269,962,327.65 from ¥272,314,296.50, a reduction of about 0.87%[55]. Expenses and Losses - The company reported a significant increase in credit impairment losses by 259.24% to CNY -419,558.60 compared to CNY -116,792.14 in the previous year[21]. - The company experienced a 57.88% increase in selling expenses, which amounted to ¥9,203,418.54 compared to ¥5,829,494.97 in the previous period[36]. - Financial expenses showed a significant negative change, with a loss of ¥13,052,943.20 compared to a loss of ¥2,940,011.16, reflecting an increase of 343.98%[36]. - Sales expenses increased to $9.20 million from $5.83 million, an increase of about 57.5%[46]. - Management expenses rose to $23.36 million from $18.51 million, reflecting an increase of approximately 26.1%[46]. Strategic Initiatives - The company plans to repurchase shares using between CNY 50 million and CNY 100 million to enhance shareholder value and implement an employee stock ownership plan[25]. - The company plans to expand its market presence and invest in new product development as part of its growth strategy[31]. - The company plans to extend the expected operational status date for a key project related to respiratory disease treatment equipment from December 2023 to December 2025[52].
美好医疗(301363) - 2024 Q1 - 季度财报